COAG Hemab Therapeutics Holdings, Inc.
P/E
--
Forward P/E
--
Price/Sales
--
Beta
--
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Hemab Therapeutics third quarter 2026 EPS missed estimates as R&D expenses rose to $24.6 million
Hemab Therapeutics reported a third quarter 2026 net loss of $27.3 million, or $0.58 per share, missing the consensus estimate of $0.51. The company remains...
Hemab Therapeutics Holdings, Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 10, 2026
Analysts expect Hemab Therapeutics to report a Q3 2026 loss per share of $0.51 on negligible revenue, with the current stock price trading at $18.42 against a...
RA Capital Discloses New $287M Stake in Hemab Therapeutics
RA Capital Management, a prominent life-sciences investor, revealed a new holding in Hemab Therapeutics (COAG) in a recent disclosure. The filing, which...